About V-type proton ATPase subunit S1
V-type proton ATPase subunit S1 (ATP6AP1) is a protein
from Homo sapiens identified by UniProt accession
Q15904, 470 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | V-type proton ATPase subunit S1 |
| UniProt accession | Q15904 |
| Gene | ATP6AP1 |
| Organism | Homo sapiens |
| Length | 470 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (109)
Diseases linked to this target (Open Targets).
- immunodeficiency 47 · score 0.75
- neurodegenerative disease · score 0.53
- congenital disorder of glycosylation type II · score 0.37
- breast adenocarcinoma · score 0.21
- genetic disorder · score 0.17
- glioblastoma multiforme · score 0.15
- breast cancer · score 0.08
- Granular Cell Tumor · score 0.07
- reading · score 0.07
- neoplasm · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15904-F1 | alphafold | PREDICTED | 78.80 | — |
Amino-acid sequence (470 residues)
MMAAMATARV RMGPRCAQAL WRMPWLPVFL SLAAAAAAAA AEQQVPLVLW SSDRDLWAPA ADTHEGHITS DLQLSTYLDP ALELGPRNVL LFLQDKLSIE DFTAYGGVFG NKQDSAFSNL ENALDLAPSS LVLPAVDWYA VSTLTTYLQE KLGASPLHVD LATLRELKLN ASLPALLLIR LPYTASSGLM APREVLTGND EVIGQVLSTL KSEDVPYTAA LTAVRPSRVA RDVAVVAGGL GRQLLQKQPV SPVIHPPVSY NDTAPRILFW AQNFSVAYKD QWEDLTPLTF GVQELNLTGS FWNDSFARLS LTYERLFGTT VTFKFILANR LYPVSARHWF TMERLEVHSN GSVAYFNASQ VTGPSIYSFH CEYVSSLSKK GSLLVARTQP SPWQMMLQDF QIQAFNVMGE QFSYASDCAS FFSPGIWMGL LTSLFMLFIF TYGLHMILSL KTMDRFDDHK GPTISLTQIV
Explore V-type proton ATPase subunit S1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets